AUTHORS

Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

The Economic 'Restart' Continues to Go Forward in Fits and Starts

Several consumer financial names are benefiting from recent trends.

2 Biotech Trades That Illustrate My Investing Strategy

Replimune Group and Akebia Therapeutics provide examples of how to approach stocks in the biotech sector.

Housing-Related Stocks Continue to Build Momentum

A small western homebuilder and a furniture maker are the latest to see their businesses improve amid the pandemic.

Rummaging Through the Bargain Bin Turns Up a Trio of Names

Beazer Homes USA, Olin Corp. and TravelCenters of America are showing signs of life and are worth consideration.

On the Lookout for Revenue Rebounds Among Covid-Dinged Biotechs

The early stages of the pandemic hurt sales at many biotech companies, but there are signs that revenue streams are picking back up.

I Don't See a Let Up in Sight for the Great Migration Going on in This Country

One thing a Democratic sweep would do is to continue or even accelerate the exodus out of high tax cities.

2021 Won't Be Like 2020 for Big Tech

There are three key reasons to think next year won't be a good as this year has been for the tech giants.

I'm Not Sold on a 'Biden Bump' for the Markets

There are reasons why equities have done well over the last week other than the rising prospects of a Biden victory next month.

2 Dinged Biotech Stocks That Could Reward Investors in the Months Ahead

Shares of Heron Therapeutics and Myovant Sciences have taken hits but both companies still show promise.

Speaking Up for Small-Caps: Why This Group Should Have Its Day Soon

There are several reasons to believe the Russell 2000 will experience catch-up trading action in the near future.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight